Daiichi Sankyo Co., Ltd: PharmaVitae Profile

Publication Date	February 2009
Publisher	Datamonitor
Product Type	Report
Pages	148
ISBN Number	not applicable
Product Code	DAT09489

Buy this product or for assistance call +44 20 7060 7474

PDF £3,425.00$5697 | €3833

FAX Order above formats by FAX

Summary

Introduction
This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Daiichi Sankyo's performance against key rivals in the prescription pharmaceutical sector

Assess the importance of Daiichi Sankyo's olmesartan antihypertensives franchise (Benicar, Benicar HCT and Azor) is to the company's outlook

Evaluate the prospects of the company's key launch product, Effient (prasugrel) which is being co-developed with Eli Lilly

Content

CHAPTER 1 ABOUT THIS PROFILE
- Executive summary
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
- Sales data
- Analyst consensus
CHAPTER 2 EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales performance, 2001-13
- Financial performance, 2001-13
- Daiichi Sankyo: PharmaVitae forecasts at a glance
- Strategic insight
- Introduction
- Product strategic insight
- Olmesartan franchise central to Daiichi Sankyo's future growth
- Uncertainty regarding generic entry
- Two scenarios for olmesartan
- Some genericization already priced into the upside scenario
- Effient: Daiichi Sankyo's much-needed new revenue stream
- M&A strategic insight
- M&A strategic insight
- Ranbaxy acquisition
- SWOT analysis
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
CHAPTER 3 QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- Product deals
- Technology deals
- M&A activity
- Company announcements
- Future product milestones
CHAPTER 4 COMPANY INTRODUCTION
- Key findings
- Background
- M&A history
- Ranbaxy acquisition
- Zenotech: opportunity in biopharmaceuticals
- Current corporate structure
CHAPTER 5 COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2001-13
- Product analysis
- Product analysis, 2001-07
- Product analysis, 2007-13
- Therapy area analysis
- Therapy area analysis, 2001-07
- Therapy area analysis, 2007-13
- Therapy area focus, 2001-13
- Geographic analysis
- Geographic analysis, 2001-07
- Geographic analysis, 2007-13
- Geographic focus, 2001-13
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2007-13
- Core analysis, 2007-13
- Expiry analysis, 2007-13
- Launch/core/expiry configuration, 2007-13
- Molecule type analysis
- Molecule type analysis, 2001-07
- Molecule type analysis, 2001-07
- Molecule type analysis, 2007-13
- Externalization analysis
- Externalization analysis, 2001-07
- Externalization analysis, 2007-13
CHAPTER 6 COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07
- Financial statements, 2001-07
- Profit and loss account, 2001-07
- Balance sheet, 2001-07
- Operating costs and profit analysis
- Operating costs and profit analysis, 2001-07
- Operating cost ratio and profit margin analysis, 2001-07
- Operating cost ratio and profit margin analysis, 2007-13
- Operating costs and profit analysis, 2007-13
- Return on capital employed analysis
- Capital employed analysis, 2001-07
- Return on capital employed (RoCE) analysis, 2001-07
CHAPTER 7 KEY PRODUCTS AND COMPETITORS
- Key findings
Overview
- Cardiovascular
- Benicar
Overview
- Sales forecast
- Benicar HCT
Overview
- Sales forecast
- Azor
Overview
- Sales forecast
- WelChol
Overview
- Sales forecast
- Mevalotin
Overview
- Sales forecast
- Hematology
- Effient
Overview
- Sales forecast
- Infectious diseases
- Cravit
Overview
- Sales forecast
- Endocrine, metabolic & genetic disorders
- Rivoglitazone
Overview
- Sales forecast
CHAPTER 8 APPENDIX
- R&D pipeline
- References
- Datamonitor Reports
- Abbreviations
- Exchange rates
List of Tables
- Table 1: Daiichi Sankyo - PharmaVitae forecasts at a glance
- Table 2: Olmesartan franchise sales forecasts, 2007-13 ($m)
- Table 3: Daiichi Sankyo key product developments, 2008
- Table 4: Daiichi Sankyo product deals and alliances, 2008
- Table 5: Daiichi Sankyo technology deals and alliances, 2008
- Table 6: Daiichi Sankyo M&A activity, 2008
- Table 7: Daiichi Sankyo company announcements, 2008
- Table 8: Daiichi Sankyo future product milestones, 2009-11
- Table 9: Daiichi Sankyo product portfolio overview ($m), 2001-07
- Table 10: Daiichi Sankyo product portfolio overview ($m), 2007-13
- Table 11: Daiichi Sankyo product portfolio overview ($m), 2001-07
- Table 12: Daiichi Sankyo product portfolio overview ($m), 2007-13
- Table 13: Daiichi Sankyo portfolio overview by geographic region ($m), 2001-07
- Table 14: Daiichi Sankyo portfolio overview by geographic region ($m), 2007-13
- Table 15: Daiichi Sankyo launch portfolio overview ($m), 2007-13
- Table 16: Daiichi Sankyo core portfolio overview ($m), 2007-13
- Table 17: Daiichi Sankyo expiry portfolio overview ($m), 2007-13
- Table 18: Daiichi Sankyo portfolio overview by molecule type ($m), 2001-07
- Table 19: Daiichi Sankyo product portfolio overview by molecule type ($m), 2007-13
- Table 20: Daiichi Sankyo product portfolio overview by source ($m), 2001-07
- Table 21: Daiichi Sankyo product portfolio overview by source ($m), 2007-13
- Table 22: Total Daiichi Sankyo sales by business unit ($m), 2001-07
- Table 23: Daiichi Sankyo profit and loss account ($m), 2001-07
- Table 24: Daiichi Sankyo balance sheet ($m), 2001-07
- Table 25: Daiichi Sankyo operating revenue/cost analysis ($m), 2001-07
- Table 26: Daiichi Sankyo operating cost ratio analysis (% of total revenues), 2001-07
- Table 27: Daiichi Sankyo operating cost ratio analysis (% of total revenues), 2007-13
- Table 28: Daiichi Sankyo operating revenue/cost analysis ($m), 2007-13
- Table 29: Daiichi Sankyo capital employed ($m), 2001-07
- Table 30: Daiichi Sankyo EBIT return on capital employed ($m), 2001-07
- Table 31: Daiichi Sankyo EBIT pre-tax return/capital employed driver analysis (%), 2001-07
- Table 32: Key products overview
- Table 33: Benicar: overview
- Table 34: Benicar: sales forecast ($m), 2007-13
- Table 35: Benicar HCT: overview
- Table 36: Benicar HCT: sales forecast ($m), 2007-13
- Table 37: Azor: overview
- Table 38: Azor: sales forecast ($m), 2007-13
- Table 39: WelChol: overview
- Table 40: WelChol: sales forecast ($m), 2007-13
- Table 41: Mevalotin: overview
- Table 42: Mevalotin: sales forecast ($m), 2007-13
- Table 43: Effient: overview
- Table 44: Effient: sales forecast ($m), 2007-13
- Table 45: Cravit: overview
- Table 46: Cravit: sales forecast ($m), 2007-13
- Table 47: Rivoglitazone: overview
- Table 48: Rivoglitazone: sales forecast ($m), 2007-13
- Table 49: Daiichi Sankyo's R&D pipeline (Phase I-registration)
- Table 50: Exchange rates, 2007
List of Figures
- Figure 1: Daiichi Sankyo prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
- Figure 2: Daiichi Sankyo's financial performance ($m), 2001-13
- Figure 3: Daiichi Sankyo: key strategic themes
- Figure 4: The differing scenarios of olmesartan and its impact on the future of Daiichi Sankyo
- Figure 5: Positive impact of Effient on Daiichi Sankyo's top line
- Figure 6: Daiichi Sankyo's newest addition: Ranbaxy subsidiary
- Figure 7: Daiichi Sankyo SWOT analysis
- Figure 8: Current corporate structure
- Figure 9: Daiichi Sankyo prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
- Figure 10: Daiichi Sankyo key sales growth driver & resistors ($m), 2001-07
- Figure 11: Daiichi Sankyo key sales growth drivers & resistors ($m), 2007-13
- Figure 12: Daiichi Sankyo prescription pharmaceutical sales by therapy area ($m), 2001-13
- Figure 13: Daiichi Sankyo prescription pharma sales by therapy area (% of total), 2001-13
- Figure 14: Daiichi Sankyo prescription pharmaceutical sales by geographic region ($m), 2001-13
- Figure 15: Daiichi Sankyo growth drivers and resistors by geographic region ($m), 2001-07
- Figure 16: Daiichi Sankyo drivers and resistors by geographic region ($m), 2007-13
- Figure 17: Daiichi Sankyo prescription pharmaceutical sales by geographic region (% of total), 2001-13
- Figure 18: Daiichi Sankyo launch/core/expiry configuration ($m), 2007-13
- Figure 19: Daiichi Sankyo prescription pharmaceutical sales by molecule type ($m), 2001-13
- Figure 20: Daiichi Sankyo growth drivers and resistors by molecule type ($m), 2007-13
- Figure 21: Daiichi Sankyo prescription pharmaceutical sales by source ($m), 2001-13
- Figure 22: Daiichi Sankyo growth drivers and resistors by source ($m), 2001-07
- Figure 23: Daiichi Sankyo growth drivers and resistors by source ($m), 2007-13
- Figure 24: Daiichi Sankyo operating revenue/cost analysis ($m), 2001-13
- Figure 25: Daiichi Sankyo operating cost ratio analysis (% of total revenues), 2001-13
- Figure 26: Daiichi Sankyo return on capital employed, EBIT margin and capital turnover, 2001-07
- Figure 27: Return on capital employed formula